Core Viewpoint - Rosen Law Firm is reminding investors who purchased Viatris Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline on June 3, 2025, for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who bought Viatris securities between August 8, 2024, and February 26, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by June 3, 2025 [2]. Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time and being ranked No. 1 for the number of settlements in 2017 [3]. - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [3]. Group 3: Case Background - The lawsuit alleges that during the Class Period, Viatris provided misleading information regarding the failed inspection of its Indore, India facility, including the issuance of an FDA warning letter that impacted the shipment of eleven products [4]. - Defendants allegedly downplayed the significance of the warning letter, referring to it as a "minor headwind," while failing to disclose critical details about the inspection, remediation efforts, and the financial implications for Viatris [5].

Core Viewpoint - A class action lawsuit has been filed against West Pharmaceutical Services, Inc. for misleading statements regarding its business performance and product demand during the specified Class Period from February 16, 2023, to February 12, 2025 [1][5]. Group 1: Lawsuit Details - The lawsuit claims that West Pharmaceutical made false and misleading statements about its visibility into customer demand and the impact of COVID-related product destocking, while in reality, it was experiencing significant destocking in its High-Value Products portfolio [5]. - It is alleged that West's SmartDose device, intended as a high-margin growth product, negatively impacted profit margins due to operational inefficiencies [5]. - The lawsuit also highlights that margin pressures could lead to costly restructuring activities, including the exit from continuous glucose monitoring contracts with long-standing customers [5]. - As a result of these issues, the positive statements made by the defendants regarding West's business and prospects were materially false or misleading [5]. Group 2: Participation Information - Investors who purchased West common stock during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, interested parties can visit the provided link or contact the law firm for more information [3][6].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Everus Construction Group, Inc. during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][3]. Group 1: Class Action Details - Investors who acquired Everus Construction common stock during the Class Period or through the spinoff from MDU Resources may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by June 3, 2025 [3]. Group 2: Legal Representation - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting their own success in recovering significant amounts for investors [4]. - The firm has achieved notable settlements, including the largest securities class action settlement against a Chinese company at the time, and has consistently ranked highly in securities class action settlements [4]. Group 3: Case Allegations - The lawsuit alleges that during the Class Period, Everus Construction made false or misleading statements regarding its backlog conversion cycle and revenue recognition, which misled investors about the company's business prospects [5].

NEW YORK, May 05, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Ibotta, Inc. (NYSE: IBTA) pursuant and/or traceable to the registration statement and related prospectus (collectively, the “Registration Statement”) issued in connection with Ibotta’s April 18, 2024 initial public offering (the “IPO”), of the important June 16, 2025 lead plaintiff deadline. SO WHAT: If you purchased Ibotta securities you may be entitled to compensation wit ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased BigBear.ai Holdings, Inc. securities between March 31, 2022, and March 25, 2025, of the June 10, 2025, deadline to become lead plaintiffs in a class action lawsuit [1] Group 1: Class Action Details - A class action lawsuit has been filed against BigBear.ai, and investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1][2] - Investors wishing to serve as lead plaintiffs must file with the court by June 10, 2025 [2] Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [3] - The firm has achieved significant settlements for investors, including over $438 million in 2019 and has been ranked highly in securities class action settlements since 2013 [3] Group 3: Case Allegations - The lawsuit alleges that BigBear.ai made false and misleading statements regarding its accounting practices, particularly related to the 2026 Convertible Notes [4] - Specific allegations include deficiencies in accounting review policies, improper accounting for the 2026 Convertible Notes, and the likelihood of needing to restate financial statements [4] - The inaccuracies in financial statements are claimed to have caused investor damages when the true details became public [4]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Skyworks Solutions, Inc. during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - The Class Period for the Skyworks securities is from July 30, 2024, to February 5, 2025, inclusive [1]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court by May 5, 2025, to serve as lead plaintiff [2]. Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time [3]. - The firm was ranked No. 1 by ISS Securities Class Action Services for the number of securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013 [3]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering significant amounts for clients [3]. Group 3: Case Allegations - The lawsuit alleges that during the Class Period, Skyworks' management provided misleading information regarding the company's expected revenue and growth potential, particularly in relation to its mobile business and technology investments [4]. - It is claimed that the management oversold the company's relationship with Apple, its largest customer, and its ability to leverage AI in the smartphone upgrade cycle [4]. - The lawsuit asserts that when the true state of affairs became known, investors suffered damages due to the misleading statements made by the defendants [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Viatris Inc. securities between August 8, 2024, and February 26, 2025, of the June 3, 2025, deadline to become lead plaintiffs in a class action lawsuit [1] Group 1: Class Action Details - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the Court by June 3, 2025, to serve as lead plaintiff [2] - The Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [3] Group 2: Case Background - The lawsuit alleges that during the Class Period, Viatris provided misleading information regarding the failed inspection of its Indore, India facility, including the issuance of an FDA warning letter that affected the shipment of eleven products [4] - Defendants allegedly downplayed the impact of the warning letter as a "minor headwind" while concealing material adverse facts about its financial implications [5] - The lack of disclosure regarding the inspection timeline, remediation efforts, and the financial impact led to investors purchasing Viatris securities at artificially inflated prices, resulting in damages when the true details emerged [5]

Core Viewpoint - A class action lawsuit has been filed against Open Lending Corporation for allegedly making materially false and misleading statements regarding its business operations and financial performance during the class period from February 24, 2022, to March 31, 2025 [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Open Lending's defendants misrepresented the capabilities of its risk-based pricing models and issued misleading statements about profit share revenue [5]. - It is alleged that Open Lending's 2021 and 2022 vintage loans were worth significantly less than their outstanding loan balances, and that the underperformance of the 2023 and 2024 vintage loans was misrepresented [5]. - The lawsuit asserts that these misleading statements led to investor damages when the true details about Open Lending's business were revealed [5]. Group 2: Participation Information - Investors who purchased Open Lending securities during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, interested parties can visit the provided link or contact the law firm for more information [3]. - A lead plaintiff must move the Court by June 30, 2025, to represent other class members in the litigation [1][3]. Group 3: Law Firm Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements for investors, including over $438 million in 2019 alone [4]. - The firm has been recognized for its success in securities class action settlements, ranking No. 1 in 2017 and consistently in the top 4 since 2013 [4]. - The firm emphasizes the importance of selecting qualified counsel with a proven history in leadership roles within class action lawsuits [4].

Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of investors who purchased securities of NAPCO Security Technologies, Inc. during the specified Class Period, alleging misleading statements regarding the company's revenue outlook and growth potential [1][5]. Group 1: Lawsuit Details - The class action lawsuit covers purchasers of NAPCO securities from February 5, 2024, to February 3, 2025 [1]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - The lawsuit claims that NAPCO made false and misleading statements about its revenue projections and growth, which led to investor damages when the truth was revealed [5]. Group 2: Next Steps for Investors - Interested investors can join the class action by visiting the provided link or contacting the law firm directly [3][6]. - A lead plaintiff must be appointed by June 24, 2025, to represent the class in the litigation [1][3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest against a Chinese company at the time [4]. - The firm has consistently ranked highly in securities class action settlements and has recovered hundreds of millions for investors [4].

NEW YORK, May 02, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Treace Medical Concepts, Inc. (NASDAQ: TMCI) between May 8, 2023 and May 7, 2024, both dates inclusive (the “Class Period”), of the important June 10, 2025 lead plaintiff deadline. SO WHAT: If you purchased Treace Medical securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrang ...